Rgenta Therapeutics Announces Strategic Alliance with GSK to …
Dec 4, 2024 · Rgenta to receive a cash upfront and pre-option milestone payments. Rgenta has the potential to receive milestone payments, royalties, and a future equity investment
Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine …
Oct 10, 2024 · GAITHERSBURG, MD, USA I October 9, 2024 I Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the European Commission granted Marketing Authorization for Novavax’s updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2705), dispersion for injection, for use in individuals aged 12 and ...
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC …
Oct 23, 2024 · New preclinical data on PRMT5-MTA inhibitor program will also be presented. NEW YORK, NY, USA I October 23, 2024 I Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in ...
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial ...
Oct 21, 2024 · Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW171 in treatment of ovarian cancer, non-small cell lung cancer (NSCLC), and other mesothelin (MSLN) expressing cancers
ESSENCE Phase 3 trial results demonstrating statistically significant ...
Nov 20, 2024 · The trial achieved both its primary endpoints, with semaglutide 2.4 mg demonstrating statistically significant and superior improvements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH compared to placebo. 1 Supportive secondary endpoints showed improvements in liver enzymes, including ...
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for …
Oct 12, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
US FDA Accepts Biologics License Application (BLA) for HLX14 ...
Oct 31, 2024 · SHANGHAI, China & JERSEY CITY, NJ, USA I October 30, 2024 I Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the US Food and Drug Administration (FDA) has accepted the Biologic License Application (BLA) for HLX14, an investigational biosimilar of PROLIA/XGEVA (denosumab).. Denosumab has been approved in various countries and regions under different trade names ...
Recursion announces first patient dosed in Phase 1/2 clinical study …
Dec 3, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Duality Biologics and GSK Enter Exclusive Option Agreement for a …
Dec 4, 2024 · PRINCETON, NJ, USA I SHANGHAI and SUZHOU, China I December 3, 2024 I Duality Biologics (“DualityBio”), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (ADC) therapeutics, today announced that it has entered into an exclusive option agreement with GSK for a potentially best-in-class ADC candidate, DB-1324.
PeptiDream Announces Second Internal Peptide …
Dec 14, 2024 · KAWASAKI, Japan I December 12, 2024 I PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo:4587) today announced its second wholly-owned peptide radiopharmaceutical development candidate arising from the company’s ongoing internal peptide radiopharmaceutical discovery and development efforts.